Key Highlights
- Cash and marketable securities were $266.3 million at July 31.
- Interim Cohort 1 data showed a 54% complete response rate.
- A BLA submission is planned to start in the fourth quarter of 2026.
- A webinar on preclinical data is scheduled for October 15.
enGene Therapeutics Inc. (NASDAQ:ENGN) is a clinical-stage biotechnology company developing detalimogene, a non-viral gene therapy for non-muscle invasive bladder cancer. Investors may be looking ahead to a cluster of fourth-quarter milestones, including updated pivotal data and the start of a Biologics License Application (BLA) with the U.S. FDA. The company reported fiscal third-quarter results on September 8, 2026, and one near-term event is a webinar scheduled for October 15.
Latest Company Context
In its results for the quarter ended July 31, 2026, enGene reported cash, cash equivalents and marketable securities of $266.3 million, up from $202.3 million at October 31, 2025. The net loss was $32.5 million ($0.47 per share), compared with $29.0 million a year earlier, and $92.5 million for the nine months. The company cited interim pivotal Cohort 1 data from its LEGEND study: a 54% complete response (CR) rate at any time, with 3.2% progression to muscle-invasive disease.
It plans a pre-BLA meeting with the FDA and initiation of a BLA submission in the fourth quarter of 2026, with updated CR and duration-of-response data of at least 12 months also expected then. In June, the company announced a workforce reduction of about 50% and several executive departures, and paused enrolment in additional LEGEND cohorts pending FDA discussions. A new cohort combining detalimogene with a polidocanol surfactant rinse has begun enrolling up to 80 patients.
Key Business Drivers
The key driver is regulatory. Detalimogene holds RMAT and Fast Track designations, and management has said a potential FDA decision could come in 2027, with a launch that year if approved; these are company expectations, not assurances. The 12-month durability data will be central to the filing's strength. Cash of $266.3 million is a strength, though the company did not state a runway, and a commercial launch would require further spending. The leadership turnover and restructuring add execution risk.
What Investors Should Watch
Near-term items include the October 15, 2026 webinar on preclinical data supporting the surfactant rinse combination; the updated Cohort 1 regulatory endpoint data in the fourth quarter; the outcome of the pre-BLA meeting; and the formal BLA initiation. Investors may also watch for any financing, hiring of commercial leadership, and the fiscal fourth-quarter report. Setbacks such as a requirement for additional data could potentially delay timelines.
A Defining Stretch Toward a Possible Filing, Without a Submission Yet
enGene is approaching a defining stretch, with a confirmed cash position and stated plans for a BLA but no submission or approval yet. The 12-month durability data and FDA feedback will decide how the filing is received.






Please wait processing your request...